NASDAQ : AVLN
Avalyn Pharma Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 25.71 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.14B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.14B |
| Enterprise Value | 739.84M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 25, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 44.33M |
| Shares Outstanding | 44.33M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +2,309.26% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 65.64% |
| Float | 27.41M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.85 |
| P/TBV Ratio | 2.85 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 33.12 |
| Quick Ratio | 32.76 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -297.29 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -26.53% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.88M |
| Employee Count | 55 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 30.16 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 44.20 |
| Average Volume (20 Days) | 396,094 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.35M |
| Short Previous Month | 2.52M |
| Short % of Shares Out | 5.31% |
| Short % of Float | 8.59% |
| Short Ratio (days to cover) | 7.21 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -110.00M |
| Pretax Income | -103.31M |
| Net Income | -103.31M |
| EBITDA | -109.80M |
| EBIT | -110.00M |
| Earnings Per Share (EPS) | -$12.34 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 352.43M |
| Total Debt | 17.11M |
| Net Cash | 396.42M |
| Net Cash Per Share | $8.94 |
| Equity (Book Value) | 398.35M |
| Book Value Per Share | 8.99 |
| Working Capital | 347.18M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -97.48M |
| Capital Expenditures | -923,000 |
| Depreciation & Amortization | 196,000 |
| Net Borrowing | 15.00M |
| Free Cash Flow | -98.40M |
| FCF Per Share | -$2.22 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | -48.14% |
| FCF Yield | -8.66% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $61.80 |
| Price Target Difference | 141.12% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |